Serious adverse events ( · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review
Adverse events: all grades · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review
Hospital‐acquired infections ( · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review
Invasive fungal infection · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review
All‐cause mortality up to 30 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
It is very uncertain whether summary of findings table ‐ Methylprednisolone changes all‐cause mortality up to 30 days compared with dexamethasone (very low certainty).
1 finding from 1 review
Intervention not reported
BPD at 28 days · Preterm neonates with respiratory distress
The intervention showed no clear difference in BPD at 28 days (low certainty).
1 finding from 1 review
Intervention not reported
Ever diagnosed as asthmatic by 7 years of age · Preterm neonates with respiratory distress
The intervention probably leads to lower ever diagnosed as asthmatic by 7 years of age (moderate certainty).
1 finding from 1 review
Intervention not reported
Duration of mechanical ventilation (days) · Preterm neonates with respiratory distress
1 finding from 1 review
Intervention not reported
Duration of supplemental oxygen (days) · Preterm neonates with respiratory distress
1 finding from 1 review
Intervention not reported
Hyperglycaemia · Preterm neonates with respiratory distress
The intervention probably leads to lower hyperglycaemia (moderate certainty).
1 finding from 1 review
Intervention not reported
Patent ductus arteriosus · Preterm neonates with respiratory distress
The intervention probably leads to higher patent ductus arteriosus (moderate certainty).
1 finding from 1 review
Intervention not reported
BPD at 36 weeks' postmenstrual age · Preterm neonates with respiratory distress
The intervention showed no clear difference in BPD at 36 weeks' postmenstrual age (moderate certainty).
1 finding from 1 review
Mortality after discharge (1‐3 months) · exacerbations of COPD
Treatment route: intravenous corticosteroid showed no clear difference in mortality after discharge (1‐3 months) compared with oral corticosteroid (moderate certainty).
1 finding from 1 review
Length of hospitalisation (days) · exacerbations of COPD
1 finding from 1 review
Adverse drug effect—hyperglycaemia · exacerbations of COPD
Treatment route: intravenous corticosteroid probably leads to higher adverse drug effect ‐ hyperglycaemia compared with oral corticosteroid (moderate certainty).
1 finding from 1 review
Arterial blood gas tension: PaO2 after 3 months mmHg · exacerbations of COPD
1 finding from 1 review
Treatment failure Need for additional treatment · exacerbations of COPD
Treatment route: intravenous corticosteroid showed no clear difference in treatment failure Need to intensify therapy compared with oral corticosteroid (moderate certainty).
1 finding from 1 review
Relapse Hospital readmission for COPD · exacerbations of COPD
Treatment route: intravenous corticosteroid showed no clear difference in relapse Hospital readmission for COPD compared with oral corticosteroid (moderate certainty).
1 finding from 1 review
Breathlessness ‐ early effect VAS 0‐10. Scale from: 0 to 10. · exacerbations of COPD
1 finding from 1 review